南财智讯9月26日电，中恒集团公告，广西投资集团有限公司（广投集团）与广西投资集团金融控股有 限公司（广投金控）签署《增资协议》《股份转让协议》，广投集团将其持有的中恒集团8.59亿股股份 （占公司总股本26.89%）作价40.71亿元增资至广投金控。增资完成后，广投集团不再直接持有中恒集 团股份，广投金控成为中恒集团控股股东。广投金控为广投集团控股子公司，实际控制人仍为广西国资 委。本次权益变动不会导致上市公司实际控制人变更。 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-81 广西梧州中恒集团股份有限公司 关于控股子公司为其控股子公司融资授信提供担保 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）控股 子公司重庆莱美药业股份有限公司（以下简称"莱美药业"）于 2025 年 9 月 19 日召开的第五届董事会第四十七次会议审议通过了《关于为控股子公司重庆迈 迪科医疗科技有限公司融资授信提供担保的议案》，同意莱美药业为其控股子公 司重庆迈迪科医疗科技有限公司（以下简称"迈迪科"）向重庆农村商业银行股 份有限公司两江分行申请的人民币 1,000 万元敞口授信额度提供连带责任保证担 保。具体担保事项以签订的相关担保合同为准。 （二） 内部决策程序 1 累计担保情况 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 重庆迈迪科医疗科技有限公司 | | --- | --- | --- | --- | | | 本次担保金额 | 1,000 | 万元的综合 ...

每经头条（nbdtoutiao）——始祖鸟深陷"炸山"风波，母公司大中华区新总裁上任才两个多月，被赞"专 业能力深厚"！安踏体育最新回应→ 每经AI快讯，中恒集团（SH 600252，收盘价：2.8元）9月22日晚间发布公告称，截至本公告披露日， 公司及子公司实际发生的对外担保余额约为3.82亿元，占公司2024年经审计归母净资产的比例为 6.34%。 2024年1至12月份，中恒集团的营业收入构成为：医药制造业占比76.26%，其他业务占比13.84%，食品 占比9.9%。 截至发稿，中恒集团市值为89亿元。 （记者 张明双） ...

Core Viewpoint - The announcement highlights that Guangxi Wuzhou Zhongheng Group Co., Ltd.'s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received drug registration certificates for two medications, Nicorandil Tablets and Ketorolac Tromethamine Injection, which will enhance the company's product line and market presence [1][3]. Group 1: Drug Registration Details - Chongqing Laimei Pharmaceutical has obtained registration for Nicorandil Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) from the National Medical Products Administration [1][5]. - Nicorandil Tablets are indicated for the treatment of angina pectoris, originally developed by Daiichi Sankyo Co., Ltd. and launched in Japan in 1983, with sales in China starting in 2006 [1][2]. - Sales projections for Nicorandil Tablets in Chinese hospitals from 2022 to 2024 are estimated at CNY 676 million, CNY 789 million, and CNY 873 million, respectively [1][2]. Group 2: Market and Financial Impact - Ketorolac Tromethamine Injection is used for the short-term treatment of moderate to severe postoperative pain, developed by Roche and approved in China in 2005 [2]. - Sales projections for Ketorolac Tromethamine Injection in Chinese hospitals from 2022 to 2024 are estimated at CNY 2.643 billion, CNY 1.892 billion, and CNY 898 million, respectively [2]. - The total R&D investment for Nicorandil Tablets and Ketorolac Tromethamine Injection by Laimei Pharmaceutical is CNY 5.3879 million and CNY 4.7431 million, respectively [2].

Core Insights - Zhongheng Group announced the approval of two drugs by the National Medical Products Administration, indicating a positive development for the company's product portfolio [2] Drug Approval Details - The approved drugs include Nicardipine Tablets (specification: 5mg) and Ketorolac Tromethamine Injection (specification: 1ml: 30mg) [2]

Core Viewpoint - Zhongheng Group has received approval for two new drugs, which may enhance its market position and revenue potential in the pharmaceutical sector [1] Company Summary - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has obtained drug registration certificates for Nicardipine Tablets and Ketorolac Tromethamine Injection from the National Medical Products Administration [1] - As of the latest report, Zhongheng Group's market capitalization stands at 9.3 billion yuan [1] Industry Summary - For the fiscal year 2024, Zhongheng Group's revenue composition is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1]

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-80 广西梧州中恒集团股份有限公司 关于控股子公司获得药品注册证书的公告 （一）尼可地尔片基本情况 1 | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，本 | | | | | --- | --- | --- | --- | --- | | | 品符合药品注册的有关要求，批准注册，发给药品注册证书。 | | | | | | 质量标准、说明书、标签及生产工艺照所附执行。药品生产企 | | | | | | 业应当符合药品生产质量管理规范要求方可生产销售。 | | | | | 药品批准文号有效期 | 至 2030 9 8 | 年 | 月 | 日 | （二）酮咯酸氨丁三醇注射液基本情况 | 药品名称 | 药品通用名称：酮咯酸氨丁三醇注射液 | | --- | --- | | | 英文名/拉丁名：Ketorolac Trometamol Injection | | 主要成份 | 酮咯酸氨丁三醇 | | 剂型 | 注射剂 | | 规格 | 1ml:30mg | | 证书编号 | 2025S02756 | | 药品注册标准编号 | YB ...

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for two drug registrations, indicating a positive development in the company's product portfolio and potential revenue growth [1] Group 1: Drug Approvals - The approved drugs include Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, which addresses a significant market need in cardiovascular health [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain, expanding the company's offerings in pain management [1]

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs, which will enhance the company's product line [1] Group 1: Drug Approvals - Laimei Pharmaceutical has obtained drug registration certificates for Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, while Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1] Group 2: R&D Investment - The total R&D investment for Nicorandil tablets was approximately RMB 5.39 million, and for Ketorolac Tromethamine injection, it was around RMB 4.74 million [1] - The approval of these drugs is expected to further enrich the company's product offerings [1]

Core Insights - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two drugs: Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) [1] Group 1 - The approval of Nicardipine Tablets and Ketorolac Tromethamine Injection is expected to enhance the company's product line [1]